AAAAAA

   
Results: 1-8 |
Results: 8
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three timesdaily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses
Authors: Kruis, W Schreiber, S Theuer, D Brandes, JW Schutz, E Howaldt, S Krakamp, B Hamling, J Monnikes, H Koop, I Stolte, M Pallant, D Ewald, U
Citation: W. Kruis et al., Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three timesdaily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses, GUT, 49(6), 2001, pp. 783-789
Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease
Authors: Cortot, A Colombel, JF Rutgeerts, P Lauritsen, K Malchow, H Hamling, J Winter, T Van Gossum, A Persson, T Pettersson, E
Citation: A. Cortot et al., Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease, GUT, 48(2), 2001, pp. 186-190
Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease
Authors: Fellermann, K Steffen, M Stein, J Raedler, A Hamling, J Ludwig, D Loeschke, K Stange, EF
Citation: K. Fellermann et al., Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease, ALIM PHARM, 14(2), 2000, pp. 171-176
Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease
Authors: Cortot, A Colombel, JF Rutgeerts, P Lauritsen, K Malchow, H Hamling, J Winter, T van Gossum, A Persson, T Pettersson, E
Citation: A. Cortot et al., Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease, DRUGS TODAY, 36, 2000, pp. 33-37
Evidence based case report - Chlamydia infection in general practice
Authors: Hicks, NR Dawes, M Fleminger, M Goldman, D Hamling, J Hicks, LJ
Citation: Nr. Hicks et al., Evidence based case report - Chlamydia infection in general practice, BR MED J, 318(7186), 1999, pp. 790-792
Evidence based case report - Treatment for head lice
Authors: Dawes, M Hicks, NR Fleminger, M Goldman, D Hamling, J Hicks, LJ
Citation: M. Dawes et al., Evidence based case report - Treatment for head lice, BR MED J, 318(7180), 1999, pp. 385-386
Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease
Authors: Schreiber, S Nikolaus, S Hampe, J Hamling, J Koop, I Groessner, B Lochs, H Raedler, A
Citation: S. Schreiber et al., Tumour necrosis factor a and interleukin 1 beta in relapse of Crohn's disease, LANCET, 353(9151), 1999, pp. 459-461
Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis
Authors: Bregenzer, N Caesar, I Andus, T Hamling, J Malchow, H Schreiber, S Scholmerich, J
Citation: N. Bregenzer et al., Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis, Z GASTROENT, 37(10), 1999, pp. 999-1004
Risultati: 1-8 |